 PF-04603629 is being investigated for the treatment of Type 2 diabetes mellitus T2DM. Specifically, PF-04603629 is a protein that is a combination of exendin-4 a glucagon-like peptide-1 GLP-1 mimetic currently marketed as Byetta fused to human transferrin a naturally occuring protein in order to increase the concentration of exendin-4 in the blood. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04603629 following multiple escalating subcutaneous doses in adult subjects with T2DM. 